Search company, investor...

ActiVein

activein.co.il

Stage

Other Investors | Alive

About ActiVein

ActiVein develops a patented, dual-action intravenous (IV) catheter that aims to replace the standard conventional "hospital IV line" by enabling both fluid infusion and blood withdrawal using a single vein over an entire hospitalization period, whereas the currently used device aims to allow, regularly, fluid infusion only.

Headquarters Location

1 Leshmem St.

Israel

Missing: ActiVein's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ActiVein's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ActiVein Patents

ActiVein has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/26/2003

7/6/2010

Fluid dynamics, Developmental biology, Animal anatomy, Animal phyla, Parasitic animals

Grant

Application Date

3/26/2003

Grant Date

7/6/2010

Title

Related Topics

Fluid dynamics, Developmental biology, Animal anatomy, Animal phyla, Parasitic animals

Status

Grant

ActiVein Frequently Asked Questions (FAQ)

  • What is ActiVein's latest funding round?

    ActiVein's latest funding round is Other Investors.

  • Who are the investors of ActiVein?

    Investors of ActiVein include Xenia Venture Capital.

  • Who are ActiVein's competitors?

    Competitors of ActiVein include Mercator MedSystems, Sequana Medical, Avantis Medical Systems, Corpora Systems, InaVein and 12 more.

Compare ActiVein to Competitors

G
Global Blood Resources

Global Blood Resources is a company that is making advances in whole blood recovery, salvaging, and transfusions.Their main product is the Hemobag which is a device that returns a patient's own blood to their body during invasive surgery. This product is an alternative to risky transfusions.

E
Exotic Technologies

After two years of development, testing and continuous improvement and trials at various hospitals, INFLO Infusion Flow Rate Monitor was introduced. INFLO is a microprocessor-controlled device with high level of accuracy, which can be used to monitor the infusion flow rate. Its low cost and low operating expenses as well as long life cycle aims to make it an alternative to the expensive infusion monitoring devices and aims to give accuracy and safety with inexpensive infusion sets.

B
Beta-O2 Technologies

Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.

O
Otothera Corporation

Otothera Corporation is a medical device company developing products to diagnose and treat the more than seven million severe tinnitus (constant ringing in the ears) sufferers in the US. The company was originally named AudioFusion. The company was a 2006 PTEN Growth Accelerator (GAP) winner.

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.